These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23840582)

  • 1. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
    Schultz NA; Christensen IJ; Werner J; Giese N; Jensen BV; Larsen O; Bjerregaard JK; Pfeiffer P; Calatayud D; Nielsen SE; Yilmaz MK; Holländer NH; Wøjdemann M; Bojesen SE; Nielsen KR; Johansen JS
    PLoS One; 2013; 8(6):e67059. PubMed ID: 23840582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40.
    Palmquist C; Dehlendorff C; Calatayud D; Hansen CP; Hasselby JP; Johansen JS
    Pancreas; 2020 Jan; 49(1):53-61. PubMed ID: 31856080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
    PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
    Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
    Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
    Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of serum YKL-40 in patients with cervical cancer.
    Roslind A; Palle C; Johansen JS; Christensen IJ; Nielsen HJ; Mosgaard BJ
    Scand J Clin Lab Invest; 2020 Dec; 80(8):687-693. PubMed ID: 33186077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer.
    Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Wagrodzki M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():141-147. PubMed ID: 28624692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer.
    Chen HT; Zheng JM; Zhang YZ; Yang M; Wang YL; Man XH; Chen Y; Cai QC; Li ZS
    Pancreas; 2017 Mar; 46(3):323-334. PubMed ID: 28099248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
    Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
    Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer.
    Videmark AN; Christensen IJ; Feltoft CL; Villadsen M; Borg FH; Jørgensen BM; Bojesen SE; Kistorp C; Ugleholdt R; Johansen JS
    Cancer Med; 2023 Mar; 12(6):6675-6688. PubMed ID: 36440611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
    Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H
    Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.
    Fuksiewicz M; Kotowicz B; Rutkowski A; Achinger-Kawecka J; Wagrodzki M; Kowalska MM
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818765209. PubMed ID: 29642772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
    Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
    Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.